Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen:: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen:: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
复制标题
DOI：
10.1016/s0140-6736(98)09201-0
复制
发表时间：
1999-05-15
期刊：
影响因子：
168.9
通讯作者：
Mouridsen, HT
中科院分区：
文献类型：
--
作者：
Overgaard, M;Jensen, MB;Mouridsen, HT
背景乳腺切除术后放疗与绝经前高危乳腺癌患者联合化疗时，局部复发率较低，无病生存率和总生存率提高。然而，同样的益处是否也适用于绝经后妇女辅助他莫昔芬治疗类似的高危癌症尚不清楚。在一项随机试验中，绝经后妇女谁经历了乳房切除术，我们比较了辅助他莫昔芬单独与他莫昔芬加术后放疗。绝经后高危乳腺癌妇女（II期或III期）随机分配辅助他莫昔芬（每日30 mg，持续1年）（689）或胸壁和局部淋巴结术后放疗（686）。中位随访时间为123个月。研究终点为首次复发部位（局部复发、远处转移或两者兼有）、无瘤和总转移、生存率。结果：放疗加他莫昔芬组52例（8%）局部复发，单纯他莫昔芬组242例（35%）局部复发（P < 0.05）。
Background Postmastectomy radiotherapy is associated with a lower locoregional recurrence rate and improved disease-free and overall survival when combined with chemotherapy in premenopausal high-risk breast-cancer patients. However, whether the same benefits apply also in postmenopausal women treated with adjuvant tamoxifen for similar high-risk cancer is unclear. In a randomised trial among postmenopausal women who had undergone mastectomy, we compared adjuvant tamoxifen alone with tamoxifen plus postoperative radiotherapy.Methods Between 1982 and 1990, postmenopausal women with high-risk breast cancer (stage II or III) were randomly assigned adjuvant tamoxifen (30 mg daily for 1 year) alone (689) or with postoperative radiotherapy to the chest wall and regional lymph nodes (686). Median follow-up was 123 months. The endpoints were first site of recurrence (locoregional recurrence, distant metastases, or both), and disease-free and overall metastases, survival.Findings Locoregional recurrence occurred in 52 (8%) of the radiotherapy plus tamoxifen group and 242 (35%) of the tamoxifen only group (p